CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

Inclusion Criteria: * Voluntary written informed consent obtained prior to any study-related procedures * Ability to read, understand, and sign the Informed Consent Form and reliably complete required study documents * Willingness to undergo medical intervention, including genetic therapy, and to comply with the visit schedule and all study procedures * Commitment to maintain a stable medication and supplement regimen throughout the study, with no initiation of new medications, supplements, or performance-enhancing substances unless approved by the Investigator * Men and women aged 45-75 years * Body mass index (BMI) between 17.0 and 30.0 kg/m² at screening * Evidence of age-related physical decline or sedentary lifestyle defined as: * \<150 minutes/week of moderate-intensity activity, or * \<75 minutes/week of vigorous activity, or * \<600 MET-minutes/week, or * Clinical Frailty Scale (CFS) score 3-6 * Active Prospera ZEDE eResidency or Physical Residency * Stable comorbid conditions for at least 3 months prior to screening * Postmenopausal status (women) * Willingness to use reliable contraception for 6 months following therapy * Low or undetectable antibody titers to AAV9 (≤1:100 by ELISA) Exclusion Criteria: * Pregnancy, breastfeeding, or intent to become pregnant; premenopausal status (unless ≥12 months amenorrhea or FSH ≥30 IU/L) * Subjects who have a history of alcohol or drug abuse within 1 year of study entry * Initiation of prohibited medications, supplements, or…